Increasing safety of allogeneic hematopoietic stem cell transplantation (allo-HSCT) has also increased the number of patients at risk for developing chronic GvHD (cGvHD). Peripheral nerve neurological manifestations and symptoms are being increasingly recognized in cGvHD, however, prospectively planned clinical studies have rarely been reported. There is a substantial lack of understanding of the mechanisms that lead to peripheral neuropathy (PN) in cGvHD and therapeutic options are profoundly limited and mostly symptomatic. Currently, myasthenia gravis, muscle cramps and PN are considered as 'other' complications related to cGvHD, whereas myositis and polymyositis are considered as 'distinctive' neurological manifestations of cGvHD. Consequently, the diagnosis of neurological cGvHD can only be established when additional 'diagnostic' manifestations of cGvHD are present and the neurological manifestations are still not incorporated into the scoring system. 1, 2 This presents an important gap, because damage of the peripheral nervous system (PNS) in the context of cGvHD can produce severe disability, morbidity and mortality. 2 In order to investigate the incidence and characteristics of PNS manifestations, with emphasis on small-fiber neuropathy (SFN), we have conducted a prospective cohort study on patients with cGvHD developed after allo-HSCT.
The study protocol consisted of hematologist work-up (evaluation and scoring performed according to 2005 NIH cGvHD Consensus recommendations), laboratory work-up for excluding common causes of PN (diabetes, folic acid, vitamin B12, zinc, selenium or copper deficiency), tissue biopsy and other subspecialist examination according to specific patient needs (neurology, dermatology, dental and so on).
3 Neurologic evaluation was focused on determination of the type and pattern of nerve damage and consisted of nerve conduction studies (NCS) for sural and peroneal nerves, quantitative sensory testing (QST), The Pain Detect Questionnaire (PDQ) and Total Neuropathy Score. 4, 5 Peripheral nerves contain different types of nerve fibers. The largest nerve fibers (A-alpha and A-beta) are involved in voluntary movements and deep sensation and they were analyzed by NCS. The small fibers (A-delta and C) are involved in the temperature and pain sensation and they were analyzed by QST. IBM SPSS Statistics 20 program was used for statistical analyses. A Kendall's Tau b correlation was run to determine the relationship between cGvHD variables and fiber damage. Fisher's exact test and χ 2 -test were used for comparison of two or three and more independent groups. A value of P o 0.05 was deemed statistically significant.
A total of 27 patients enrolled in this study were referred to neurology for neuromuscular complications analysis. Prior laboratory work-up showed no significant micronutrient deficiencies that are associated with PN. None of the patients had pre-existing neuropathy or underlying disorder that could lead to PN. Patients' characteristics are shown in Table 1 . Clinical and/or electrophysiological signs of PN were observed in 25 (92.6%) patients with predomination of mixed small and large fiber neuropathy (LFN; n = 18, 66.7%). Twenty-two (81.5%) patients had signs of LFN on NCS, mostly axonal sensorimotor type (n = 18, 66.7%). Twenty-one (77.8%) patients had abnormal finding on QST, mostly with both A-delta and C-fibers damaged (n = 10, 37%). A-delta fibers were damaged in 17 (63%) and C-fibers in 14 (51.9%) patients. Neurological examination findings are shown in Table 2 .
Correlation was run to determine the relationship between different cGvHD variables and specific findings indicating peripheral nerve damage ( Table 3 ). The intensity of immunosuppression showed moderately strong association with A-beta fiber damage (τb = 0.576, P = 0.002). cGvHD of lung had moderately strong negative correlation with A-delta and A-beta fiber damage (τb = − 0.655, P = 0.000; τb = − 0.526, P = 0.005 respectively). cGvHD of mouth had weak to moderately strong negative correlation with muscle cramps (τb = − 0.374, P = 0.044). Weak to moderately strong positive correlation (τb = 0.443, P = 0.015) was established between cGvHD of skin and A-delta fiber damage. For five patients who received MAC the therapy data were missing or incomplete. Moderately strong, negative correlation was established between cyclophosphamide and A-beta fiber damage (τb = − 0.624, P = 0.004). Weak to moderately strong, positive correlation considering A-delta and moderately strong correlation considering A-beta fiber damage was found for fludarabine (τb = 0.498, P = 0.022 and τb = 0.516, P = 0.018, respectively). Moderately strong correlation was found between TBI and neuropathic pain (τb = 0.470, P = 0.016). Several significant differences were found comparing patients who received reduced intensity conditioning (RIC) and patients who received myeloablative conditioning (MAC), as well as between patients who received PBSC or bone marrow stem cells (BMSC). A-delta and A-beta fiber damage was significantly higher in patients who received RIC than MAC, and PBSC than BMSC (P = 0.018 and P = 0.040, P = 0.006 and 0.022, respectively). Patients who received RIC and patients who received PBSC, had significantly higher incidence of SFN (mostly combined A-delta and C-fiber neuropathy) and mixed (small and large) fiber neuropathy comparing with patients who received MAC or BMSC (P = 0.025 and P = 0.007, respectively). Considering pure LFN the trend was the same, but did not reach the level of statistical significance.
This study shows a high prevalence (92.6%) of clinical and/or electrophysiological signs of PN, predominantly mixed SFN and LFN (66.7%). The results of studies in cGvHD patients also show that PNS damage is very common. 6, 7 Painful muscle cramps are present in a significant proportion of cGvHD patients (33.3% here and 50% in study of Kraus et al.) . 6 The neurologic assessment in our study was done at a 21-month median after allo-HSCT, when a significant number of patients were found to have very advanced neuropathy. Kraus et al. 6 found that muscle cramps are more frequently present in patients with milder forms of neuropathy, whereas in advanced forms they diminish. According to our results, a large proportion of cGvHD patients (77.8%) have SFN (A-delta fibers are more frequently affected). However, whether this is a specific subtype of cGvHD neuropathy and associated with specific symptoms (muscle cramps or neuropathic pain) is currently unknown.
In this current study, prior fludarabine was associated with PN, which is a new observation. Some therapeutic agents may activate the mitochondrial-based apoptotic pathway, which seems to have a role in toxic neuropathy development. 8 Also, PN is a wellrecognized manifestation of mitochondrial inherited diseases. 9 Changes in mitochondrial dysfunction may contribute to the appearance of neuropathy in diabetes, especially in insulin neuritis, a rare iatrogenic form of SFN. 10, 11 The calcium-ion homeostasis dysregulation, together with possible altered function of blood-nerve barrier, may also be involved in this scenario. 12 It is challenging to point to a specific mechanism of toxic peripheral nerves damage in cGvHD, because of interplay of Abbreviations: AA = aplastic anaemia; allo-HSCT = allogeneic hematopoietic stem cell transplantation; ATG = antithymocyte globulin; CSP = cyclosporine; cGvHD = chronic GvHD; MAC = myeloablative conditioning; MDS = myelodysplastic syndrome; MMF = mycophenolate mofetil; MTX = methothrexate; RIC = reduced intensity conditioning; PNH = paroxysmal nocturnal hemoglobinuria. Abbreviations: LE = lower extremities; LFN = large fiber neuropathy; NCS = nerve conduction studies; PDQ = pain detect questionnaire; SFN = small-fiber neuropathy; TNS = total neuropathy score; QST = quantitative sensory testing. a NCS were performed on Medelec Synergy Multimedia EMG/EP, Oxford Instruments; surface stimulation-bipolar electrodes, cathode/anode distance 2.5 cm (TECA/Medelec, reusable bipolar stimulating electrode); compound muscle action potential (CMAP)-TECA/Medelec bar recording electrode 20 mm; sensory nerve action potential (SNAP) -TECA/Medelec 'digital ring electrodes' .
b QST was performed on CHEPS/PATHWAY with surface thermal stimuli according to protocols levels and limits based on standardized tests with random warm and cold stimuli. The magnitude of the correlation coefficient was used to gauge the strength of the correlation as follows: |τb|40.70 strong, 0.50 o |τb| o0.70 moderately strong, 0.30o |τb| o0.50 weak to moderately strong and |τb|o 0.30 weak correlation. a Statistically significant.
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In toxic neuropathies one usually finds axonal damage due to cytoskeleton damage or altered apoptotic mechanisms, whereas in autoimmune neuropathies the typical finding is demyelination of large fibers. This paradigm, however, has some exceptions. In some autoimmune neuropathies like acute or chronic inflammatory demyelinating neuropathy (AIDP and CIDP), it is also possible to find damage of unmyelinated or poorly myelinated fibers, primarily resulting in neuropathic pain and autonomic dysfunction. cGvHD entity most closely resembles an autoimmunemediated inflammatory disease and these typical autoimmune neuropathies could represent models of nerve damage in cGvHD as well. However, CIDP and AIDP have previously been reported to be present in only 2-3% of cGvHD patients. 13 Clinical symptoms found in cGvHD patients (pain with some characteristics of neuropathic pain, painful muscle cramps, paraesthesia, sensory and/or motor loss, and attenuated myotatic reflexes) could reflect the unique and complex pathophysiology of this distinct disease entity and the importance of SFN in the background of the PNS manifestations in cGvHD.
Significant, positive correlation was established between cGvHD of skin and A-delta fiber damage. It is difficult to say whether A-delta neuropathy is caused only by cGvHD, or A-delta fibers are damaged directly by skin changes in cGvHD. PN occurs at a higher frequency in scleroderma, but these findings cannot be ascribed to compression neuropathies, but rather involvement of large and small fibers in a non-length-dependent manner.
14,15 Dominant A-delta neuropathy found in our study may indicate cGvHDmediated damage, because C-fibers (tiny unmyelinated) are more vulnerable to mechanical compression, whereas A-delta fibers (small myelinated) are more vulnerable to demyelination and autoimmune diseases.
Association of RIC (in contrast to MAC) and transplantation of PBSC (in contrast to BMSC) with specific peripheral nerve damage and SFN strongly suggests the implication of immune-mediated mechanisms in cGvHD related neuropathy, rather than transplantconditioning-induced damage.
In spite of several limitations of this study (relatively small sample, different duration of cGvHD among patients at the beginning of the study, a lack of follow-up, which would enable insight into the dynamics of the changes), it still provides compelling evidence of the magnitude of the problem. The presented data show high prevalence of SFN or LFN in cGvHD patients. Future studies, with larger sample, monitored for a longer time period with collection of the control data in transplanted patients without cGvHD, may address some of the unsolved questions. Factors contributing to the development of neuropathy should be vigorously studied, as therapeutic options are mostly symptomatic. It is clear, however, that peripheral nerve damage has a central place in cGvHD and development of better monitoring and treatment strategies should be a focus of future clinical investigations.
